

Supp. Table S1. Molecular Genetic Testing Prior to Exome Sequencing for Selected Projects*

FORGE ID	Molecular genetic testing prior to exome sequencing for selected projects
109	SCA1,2,3,6,7,8,17, <i>FXN</i> , <i>SACS</i> **
C1012	<i>FMR1</i> , <i>APTX</i> , <i>PDSS2</i> , <i>PDSS1</i> , <i>CoQ9</i> , <i>CoQ2</i> , <i>POLG</i>
171	SCA1,2,3,6,7,8,17, <i>FXN</i> , <i>CMT1A</i> , <i>CMT1B</i> , <i>CMTX</i> , <i>C10orf2</i> , <i>GJB6</i>
254	SCA1,2,3,6,7,8,17, <i>APTX</i> , <i>FRAAXE</i> , <i>ATM</i> , <i>CABC1</i> , <i>POLG</i> , <i>C10orf2</i> , mt deletions
C1008	SCA1,2,3,6,7,8,17, <i>FXN</i> , <i>PLP1</i> , mtDNA Seq., <i>POLG</i> , <i>ANT1</i> , <i>C10orf2</i> , <i>CYP7B1</i> , <i>SACS</i> , <i>SPG15</i> , 20, 7, 21, 44, <i>CCT5</i> , <i>PNPLA6</i>
C1026	SCA1,2,3,6,7,8,17, <i>FXN</i> , mtDNA Seq., <i>POLG</i> , <i>ANT1</i> , <i>C10orf2</i> , <i>CYP7B1</i> , <i>SACS</i> , <i>SPG15</i> , 20, 7, 21, 44, <i>CCT5</i> , <i>PNPLA6</i>

*representative of different clinicians from two provinces

**French Canadian mutations only